These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1525 related items for PubMed ID: 31227373

  • 1. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P.
    Lancet; 2019 Aug 03; 394(10196):385-395. PubMed ID: 31227373
    [Abstract] [Full Text] [Related]

  • 2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A.
    Lancet Oncol; 2021 Feb 03; 22(2):235-245. PubMed ID: 33444529
    [Abstract] [Full Text] [Related]

  • 3. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L.
    Lancet Oncol; 2016 Apr 03; 17(4):464-474. PubMed ID: 26968359
    [Abstract] [Full Text] [Related]

  • 4. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L.
    Lancet Oncol; 2015 Mar 03; 16(3):274-83. PubMed ID: 25656287
    [Abstract] [Full Text] [Related]

  • 5. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
    Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N, PACE Trial Investigators.
    Lancet Oncol; 2019 Nov 03; 20(11):1531-1543. PubMed ID: 31540791
    [Abstract] [Full Text] [Related]

  • 6. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F.
    Lancet Oncol; 2016 Aug 03; 17(8):1061-1069. PubMed ID: 27339116
    [Abstract] [Full Text] [Related]

  • 7. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
    Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E.
    Lancet Oncol; 2015 Dec 03; 16(16):1605-16. PubMed ID: 26522334
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hypofractionation for clinically localized prostate cancer.
    Hickey BE, James ML, Daly T, Soh FY, Jeffery M.
    Cochrane Database Syst Rev; 2019 Sep 03; 9(9):CD011462. PubMed ID: 31476800
    [Abstract] [Full Text] [Related]

  • 10. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
    Mutter RW, Giri S, Fruth BF, Remmes NB, Boughey JC, Harless CA, Ruddy KJ, McGee LA, Afzal A, Gao RW, Shumway DA, Vern-Gross TZ, Villarraga HR, Kenison SL, Kang Y, Wong WW, Stish BJ, Merrell KW, Yan ES, Park SS, Corbin KS, Vargas CE.
    Lancet Oncol; 2023 Oct 03; 24(10):1083-1093. PubMed ID: 37696281
    [Abstract] [Full Text] [Related]

  • 11. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX.
    Lancet Oncol; 2019 Mar 03; 20(3):352-360. PubMed ID: 30711522
    [Abstract] [Full Text] [Related]

  • 12. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
    Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N, PACE Trial Investigators.
    Lancet Oncol; 2022 Oct 03; 23(10):1308-1320. PubMed ID: 36113498
    [Abstract] [Full Text] [Related]

  • 13. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
    Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Bloomfield DJ, Chan C, Cleator S, Coles CE, Donovan E, Fleming H, Glynn D, Goodman A, Griffin S, Hopwood P, Kirby AM, Kirwan CC, Nabi Z, Patel J, Sawyer E, Somaiah N, Syndikus I, Venables K, Yarnold JR, Bliss JM, FAST-Forward Trial Management Group.
    Health Technol Assess; 2023 Nov 03; 27(25):1-176. PubMed ID: 37991196
    [Abstract] [Full Text] [Related]

  • 14. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
    Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E.
    Lancet Oncol; 2012 Jan 03; 13(1):43-54. PubMed ID: 22169269
    [Abstract] [Full Text] [Related]

  • 15. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J, Jaksic B, Prpic M, Kust D, Bahl A, Budanec M, Prgomet Secan A, Franco P, Kruljac I, Spajic B, Babic N, Kruslin B, Zovak M, Zubizarreta E, Rosenblatt E, Fröbe A.
    Radiat Oncol; 2021 May 12; 16(1):88. PubMed ID: 33980277
    [Abstract] [Full Text] [Related]

  • 16. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G, Riva G, Ciardo D, Gandini S, Fodor C, Zerini D, Colangione SP, Timon G, Comi S, Cambria R, Cattani F, De Cobelli O, Orecchia R, Jereczek-Fossa BA.
    Med Oncol; 2018 May 10; 35(6):96. PubMed ID: 29748830
    [Abstract] [Full Text] [Related]

  • 17. External beam radiation dose escalation for high grade glioma.
    Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN.
    Cochrane Database Syst Rev; 2020 May 21; 5(5):CD011475. PubMed ID: 32437039
    [Abstract] [Full Text] [Related]

  • 18. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
    Royce TJ, Lee DH, Keum N, Permpalung N, Chiew CJ, Epstein S, Pluchino KM, D'Amico AV.
    Eur Urol Focus; 2019 Jul 21; 5(4):577-584. PubMed ID: 29221876
    [Abstract] [Full Text] [Related]

  • 19. Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation.
    Jereczek-Fossa BA, Surgo A, Maisonneuve P, Maucieri A, Gerardi MA, Zerini D, Marvaso G, Ciardo D, Volpe S, Rojas DP, Riva G, Alessandro O, Dicuonzo S, Fanetti G, Romanelli P, Starzyńska A, Cattani F, Cambria R, Fodor C, Garibaldi C, Romanò C, De Cobelli O, Orecchia R.
    Radiol Med; 2019 Jan 21; 124(1):65-78. PubMed ID: 30219945
    [Abstract] [Full Text] [Related]

  • 20. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
    Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L.
    Int J Radiat Oncol Biol Phys; 2019 Mar 15; 103(4):823-833. PubMed ID: 30458234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.